This article is a retraction of:
RETRACTED: CSF p-tau as a potential cognition impairment biomarker in ALS
Frontiers Editorial OfficeA Retraction of the Original Research Article
CSF p-tau as a potential cognition impairment biomarker in ALS
by Gong, Z., Gao, L., Lu, Y., and Wang, Z. (2022). Front. Neurol. 13:991143. doi: 10.3389/fneur.2022.991143
The journal retracts the 01 November 2022 article cited above.
Following publication, concerns were raised regarding the validity of the data in the article. The authors failed to provide the raw data during the investigation, which was conducted in accordance with Frontiers' policies. Given the lack of raw data, the editors no longer have confidence in the findings presented. The article is therefore retracted.
This retraction was approved by the Chief Editors of Frontiers in Neurology and the Chief Executive Editor of Frontiers. The authors agree to this retraction.
Frontiers would like to thank the concerned reader who contacted us regarding the published article.
Citation: Frontiers Editorial Office (2024) Retraction: CSF p-tau as a potential cognition impairment biomarker in ALS. Front. Neurol. 15:1392563. doi: 10.3389/fneur.2024.1392563
Received: 27 February 2024; Accepted: 27 February 2024;
Published: 04 March 2024.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2024 Frontiers Editorial Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Editorial Office, research.integrity@frontiersin.org